Mingjia Li, MD, discussed the limitations of current biomarkers in selecting patients with resectable NSCLC for neoadjuvant ...

The study found that patients exhibited a low rate of severe side effects after returning home, supporting less-intensive ...

Heath Skinner, MD, PhD, discussed which new radiation oncology service lines community practices can implement, how leadership decides, and what launches require.

Heath Skinner, MD, PhD, discussed the 3 considerations that determine which new radiation oncology service lines his network chooses to build.

The investigators report that the phase 1 portion of the COMPARE trial met its safety end point and cleared the study to ...

Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy ...

Presentations at ESMO Congress 2026 detailed how surgery, radiation oncology, and supportive care can contribute to the ...

Zev A. Wainberg, MD, MSc, discussed why neither the first-line regimen nor the second-line chemotherapy comparator altered ...

Bispecific antibodies targeting PD-L1 showed activity across first-, second-, and later-line advanced neuroendocrine ...

A bispecific in biliary tract cancer, dostarlimab organ preservation in rectal cancer, and KRAS G12D data in pancreatic cancer stood out at ESMO 2026.

In a phase 3 trial, the Breast Cancer Locator was noninferior to wire localization and lowered positive margin rates in ...

If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the ...